



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description  | Value(s) | Reference Range | Unit        |
|---|----------|-----------------|-------------|
| <b><u>CBC; Complete Blood Count</u></b>                             |          |                 |             |
| Hemoglobin (Hb)*<br>Method : Cynmeth Photometric Measurement        | 11.9     | 12.0 - 15.0     | gm/dL       |
| Erythrocyte (RBC) Count*<br>Method : Electrical Impedence           | 3.92     | 3.8 - 4.8       | mil/cu.mm   |
| Packed Cell Volume (PCV)*<br>Method : Calculated                    | 33.5     | 36 - 46         | %           |
| Mean Cell Volume (MCV)*<br>Method : Electrical Impedence            | 85.46    | 83 - 101        | fL          |
| Mean Cell Haemoglobin (MCH)*<br>Method : Calculated                 | 30.36    | 27 - 32         | pg          |
| Mean Corpuscular Hb Concn. (MCHC)*<br>Method : Calculated           | 35.52    | 31.5 - 34.5     | gm/dL       |
| Red Cell Distribution Width (RDW)*<br>Method : Electrical Impedence | 12.7     | 11.6 - 14.0     | %           |
| Total Leucocytes (WBC) Count*<br>Method : Electrical Impedence      | 4900     | 4000-10000      | cell/cu.mm  |
| Neutrophils*<br>Method : VCSn Technology                            | 65       | 40 - 80         | %           |
| Lymphocytes*<br>Method : VCSn Technology                            | 27       | 20 - 40         | %           |
| Monocytes*<br>Method : VCSn Technology                              | 7        | 2 - 10          | %           |
| Eosinophils*<br>Method : VCSn Technology                            | 1        | 1 - 6           | %           |
| Basophils   | 0        | 0 - 1           |             |
| Platelet Count*<br>Method : Electrical Impedence                    | 2.63     | 1.5 - 4.5       | Lakhs/cu.mm |
| Mean Platelet Volume (MPV)*<br>Method : Electrical Impedence        | 6.9      | 7.2 - 11.7      | fL          |

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2,  
Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description            | Value(s) | Reference Range | Unit |
|-----------------------------|----------|-----------------|------|
| PCT*<br>Method : Calculated | 0.181    | 0.2 - 0.5       | %    |
| PDW*<br>Method : Calculated | 14.4     | 9.0 - 17.0      | %    |

Tests done on Automated Three Part Cell Counter. (WBC, RBC, Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.

### Esr, Erythrocyte Sedimentation Rate

**Esr, Erythrocyte Sedimentation Rate (Westergren)**      **60**      0-20      mm/hr

#### **Interpretation:**

- It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

### Blood Group & Rh Type

**Blood Grouping & Rh Typing**      "A" POSITIVE (+VE)

Method : Forward and Reverse By Tube Method

#### **Methodology**

This is done by forward and reverse grouping by tube Agglutination method.

#### **Interpretation**

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2-4 years).

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2, Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us



[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description  | Value(s)   | Reference Range  | Unit  |
|---|------------|--|-------|
| <b><u>Fasting - Glucose</u></b>   |            |  |       |
| <b>Glucose Fasting*</b><br>Method : Plasma, Hexokinase                        | <b>104</b> | Normal: 70-100<br>Impaired Fasting Glucose (IFG):<br>101-125<br>Diabetes Mellitus: >125  | mg/dL |
| <b><u>Fasting Urine Sugar</u></b>   |            |  |       |
| Fasting Urine Glucose   | Negative   | Negative   |       |
| <b><u>Stool Complete Exam</u></b>   |            |  |       |
| <b><u>Lipid Profile</u></b>   |            |  |       |
| Cholesterol-Total<br>Method : Serum, Cholesterol oxidase esterase, peroxidase | 150        | Desirable: <= 200<br>Borderline High: 201-239<br>High: > 239<br>Ref: The National Cholesterol<br>Education Program (NCEP) Adult<br>Treatment Panel III Report. | mg/dL |
| Triglycerides<br>Method : Serum, Enzymatic, endpoint                          | 188        | Normal: < 150<br>Borderline High: 150-199<br>High: 200-499<br>Very High: >= 500  | mg/dL |
| Cholesterol-HDL Direct<br>Method : Serum, Direct measure-PEG                  | 40         | <40: Low<br>40 - 60: Optimal<br>> 60: Desirable  | mg/dL |

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2,  
Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description                                    | Value(s) | Reference Range   | Unit  |
|---|----------|---|-------|
| LDL Cholesterol<br>Method : Serum                   | 72.40    | Optimal: < 100<br>Near optimal/above optimal: 100-129<br>Borderline high: 130-159<br>High: 160-189<br>Very High: >= 190 | mg/dL |
| Non - HDL Cholesterol, Serum<br>Method : calculated | 110      | Desirable: < 130 mg/dL<br>Borderline High: 130-159mg/dL<br>High: 160-189 mg/dL<br>Very High: > or = 190 mg/dL           | mg/dL |
| VLDL Cholesterol<br>Method : calculated             | 37.60    | 6 - 38  | mg/dL |
| CHOL/HDL RATIO<br>Method : calculated               | 3.75     | 3.5 - 5.0   | ratio |
| LDL/HDL RATIO<br>Method : calculated                | 1.81     | Desirable / low risk - 0.5 -3.0<br>Low/ Moderate risk - 3.0- 6.0<br>Elevated / High risk - > 6.0                        | ratio |

**Note:** 8-10 hours fasting sample is required.

### Liver Function Test

|   |      |                            |       |
|---|------|----------------------------|-------|
| Bilirubin - Total<br>Method : Serum, Diazotization  | 0.6  | Adults and Children: < 1.2 | mg/dL |
| Bilirubin - Direct<br>Method : Serum, Diazotization | 0.2  | Adults and Children: < 0.5 | mg/dL |
| Bilirubin - Indirect<br>Method : Serum, Calculated  | 0.40 | 0.1 - 1.0                  | mg/dL |
| SGOT<br>Method : Serum, UV with P5P, IFCC 37 degree | 29   | < 50                       | U/L   |
| SGPT<br>Method : Serum, UV with P5P, IFCC 37 degree | 21   | < 50                       | U/L   |

**Dr.CH.Deepthi Chandrika**  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2, Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description  | Value(s) | Reference Range   | Unit  |
|---|----------|-------------------|-------|
| Alkaline Phosphatase-ALPI<br>Method : Serum, PNPP, AMP Buffer, IFCC 37 degree | 89       | 30-120            | U/L   |
| Total Protein<br>Method : Serum, Biuret, reagent blank end point              | 7.2      | 6.6 - 8.3         | g/dL  |
| Albumin<br>Method : Serum, Bromocresol purple                                 | 4.6      | Adults: 3.5 - 5.2 | g/dL  |
| Globulin<br>Method : Calculated   | 2.60     | 1.8 - 3.6         | g/dL  |
| A/G Ratio<br>Method : Calculated  | 1.77     | 1.2 - 2.2         | ratio |

#### **KIDNEY FUNCTION TEST**

|  |       |           |       |
|--|-------|-----------|-------|
| Urea *<br>Method : Serum                           | 35    | 15- 50    | mg/dL |
| Blood Urea Nitrogen-BUN*<br>Method : Serum, Urease | 16.36 | 7 - 24    | mg/dL |
| Uric Acid*<br>Method : Serum, Uricase/POD          | 5.9   | 2.6 - 6.0 | mg/dL |
| Creatinine*<br>Method : Serum, Jaffe IDMS          | 1.0   | 0.6 - 1.1 | mg/dL |

#### **Urine Routine**

|                            |               |               |
|----------------------------|---------------|---------------|
| Colour*                    | <b>Yellow</b> |               |
| Transparency (Appearance)* | Clear         | Clear         |
| Reaction (pH)*             | 5.0           | 4.5 - 8       |
| Specific Gravity*          | 1.020         | 1.010 - 1.030 |

#### **Chemical Examination (Automated Dipstick Method) Urine**

|                |          |          |
|----------------|----------|----------|
| Urine Glucose* | Negative | Negative |
| Urine Protein* | Negative | Negative |

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2, Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description                     | Value(s) | Reference Range       | Unit |
|--------------------------------------|----------|-----------------------|------|
| Urine Ketone*                        | Negative | Negative              |      |
| Blood*                               | Negative | Negative              |      |
| Bilirubin*                           | Negative | Negative              |      |
| Nitrite*                             | Negative | Negative              |      |
| Leucocytes*                          | Negative | Negative              |      |
| Urobilinogen*                        | Normal   | With in normal limits |      |
| <b>Microscopic Examination</b> Urine |          |                       |      |
| Pus Cells (WBCs)*                    | 2-3      | 0 - 5                 | /hpf |
| Epithelial Cells*                    | 1-2      | 0 - 4                 | /hpf |
| Red blood Cells*                     | Absent   | Absent                | /hpf |
| Crystals*                            | Absent   | Absent                |      |
| Cast*                                | Absent   | Absent                |      |
| Bacteria*                            | Absent   | Absent                |      |

### **HBA1C (Glycosylated Haemoglobin)**

|                                |        |  |       |
|--------------------------------|--------|--|-------|
| Glyco Hb (HbA1C)               | 5.5    | Non-Diabetic: <=5.9<br>Pre Diabetic:6.0-6.4<br>Diabetic: >=6.5 | %     |
| Method : EDTA Whole blood,HPLC |        |  |       |
| Estimated Average Glucose :    | 111.15 |  | mg/dL |

#### Interpretations

1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
2. Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.

**Dr.CH.Deepthi Chandrika**  
M.D. Pathology  
Reg.No.APCM/FMR/77174

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2, Danavaipeta, Rajahmundry. Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description                   | Value(s) | Reference Range | Unit |
|------------------------------------|----------|-----------------|------|
| Excellent control-6-7 %            |          |                 |      |
| Fair to Good control – 7-8 %       |          |                 |      |
| Unsatisfactory control – 8 to 10 % |          |                 |      |
| Poor Control – More than 10 %      |          |                 |      |

### **Thyroid Function Test ( TFT)**

|  |       |   |        |
|--|-------|---|--------|
| TRI-IODO THYRONINE (T3)<br>Method : CLIA           | 1.247 | 0.60 - 1.81   | ng/mL  |
| TOTAL THYROXINE (T4)<br>Method : CLIA              | 7.142 | 4.2 - 12.0  | ug/dL  |
| THYROID STIMULATING HORMONE (TSH)<br>Method : CLIA | 1.376 | 0.46 – 8.10 : 1 Yrs – 5 Yrs<br>0.36 – 5.80 : 6 Yrs – 18 Yrs<br>0.35 – 5.50 : >18 Yrs<br>Pregnancy Ranges<br>1st Trimester :0.1 - 2.5<br>2nd Trimester :0.2 - 3.0<br>3rd Trimester:0.3 - 3.0 | uIU/mL |

#### **Comments:**

IF NOT ON DRUGS SUGGESTED FT3 & FT4 ESTIMATION

**Please correlate with clinical conditions.**

**Note :** Serum T3, T4 and TSH form the three components of thyroid screening panel, useful in diagnosing various disorders of the thyroid gland. Primary Hypothyroidism is accompanied by depressed serum T3 and T4 values and elevated serum TSH levels. Although elevated TSH levels are nearly always indicative of Primary Hypothyroidism, rarely they can from TSH secreting pituitary tumors (Secondary hyperthyroidism)To confirm diagnosis - evaluate FT3 and FT4.

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

Approved by

Scan to Validate



#76-4-26, GVB Plaza Meduri Street, Opp. Raju Neuro, Hospital, Gandhipuram - 2,  
Danavaipeta, Rajahmundry.Email: [timediagnosics@gmail.com](mailto:timediagnosics@gmail.com) Cell: 9615322777

Flower us —

[www.timediagnosics.in](http://www.timediagnosics.in)



**TIME DIAGNOSTICS**  
(A Unit of Time Health Care)

**Patient Name :** MRS. M. ROSE MERY

**Age / Gender :** 56 years / Female

**Patient ID :** 30406

**Source :** MEDI WHEEL

**Referral :** SELF

**Collection Time :** Nov 25, 2023, 10:08 a.m.

**Reporting Time :** Nov 25, 2023, 02:34 p.m.

**Sample ID :**



667958441

| Test Description | Value(s) | Reference Range | Unit |
|------------------|----------|-----------------|------|
|------------------|----------|-----------------|------|

**Pap Smear**

The PAP Smear is not a diagnostic procedure and should not be used as the sole means to evaluate cervical cancer. It is a screening procedure to aid in detection of cervical cancer and its precursors.

The foundation of Liquid Based Cytology (LBC) is that it produces uniform, thin layer slides and minimizes obscuring artefacts as, blood and mucus. On balance, LBC provides consistent improvement compared with conventional PAP testing in specimen adequacy and detection of LSIL and HSIL categories.

Cervico - vaginal cytology is screened & reported as per the Bethesda 2014.

**References :**

1. Johnson J and Patnick J. 2000. Achievable standards, benchmarks for reporting, and criteria for evaluating cervical cytopathology. Revised 2nd Edition.NHSCSP Publications ?NHS Cancer Screening Programmes.
2. Bankhead C, Austoker J, Davey C. 2003. Cervical Screening Results Explained ?a guide for primary care. NHS Cancer Screening Programme.
3. Gibb RK, Martens MG. The Impact of Liquid Based Cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 2011; 4(Suppl 1):S2-S11.
4. The Bathesda system for reporting cervical cytology, 2014, 3rd Edition.

**Post Prandial Urine Sugar**

**Post Prandial Blood Sugar**

|  |            |               |              |
|--|------------|---------------|--------------|
| <b>Blood Glucose-Post Prandial*</b>    | <b>167</b> | <b>70-140</b> | <b>mg/dL</b> |
| <b>Method : Plasma - P, Hexokinase</b> |            |               |              |

**\*\*END OF REPORT\*\***

**Dr.CH.Deepthi Chandrika**  
**M.D. Pathology**  
**Reg.No.APCM/FMR/77174**

**Approved by**

**Scan to Validate**

